Efficacy and security of 3 analogues of L‐carnitine in vitro and in vivo models

Abstract

The metabolic syndrome (MS) is the common denominator of the relationship between Diabetes Mellitus and cardiovascular risk. The L‐carnitine has proven to be effective in treating a variety of diseases, among them Diabetes Mellitus and hyperlipidemia. The aim was to evaluate the efficacy and security of 3 analogues of L‐carnitine. In vitro model we developed a tolerance to glucose (g) in liver cells, the cells were treated with L‐carnitine and 3 analogues, it was determinate the intracellular values of glucose, cholesterol (c) triglycerides (t) and glycogen (gy). In vivo model we developed a MS model in rats, were treated only with the analogue 3 and evaluated the serum levels of g, c and t, as well as the gy levels in liver and muscle. In vitro and in vivo assay demonstrated that analogue 3 was safe in cells and rats. The results showed a change in the intracellular levels of g, c and t in the liver cells treated with the analogue 2 and 3 and decrease in the serum levels of g and t in rats. The security evaluation did not show evidences of alterations on cell viability and proliferation in human cell lines treated with the analogues and only was observed an increase in the lymphocyte levels in rats. In conclusion, the analog 3 was effective and safe in this study. Research support CONACYT 131321.